Indegene Acquires US Health-Tech Specialist Medical Marketing Economics | Livingsights
News Technology

Indegene Acquires US Health-Tech Specialist Medical Marketing Economics

Indegene Acquires US Health-Tech Specialist Medical Marketing Economics
Written by Neha Verma

Bengaluru-headquartered Indegene, a technology-led healthcare solutions provider for big pharma and biotech companies, has acquired US-based Medical Marketing Economics (MME), a global niche leader in drug pricing, reimbursement, and market access (PRMA) services.

MME specializes in advising life sciences organizations and emerging biotech companies on determining pricing and reimbursement, contracting strategy, tactics, and custom payer market research to optimize market value for their innovations. Its team has a cumulative 300 years of pharma market access, pricing and reimbursement experience, Indegene said.

“They have vast experience in rare diseases, oncology, orphan drugs, biosimilars and newer technologies like gene therapy and CAR-T and their 40 plus the strong team have proven PRMA capabilities that complement our co-commercialization solutions”, Indegene co-founder and CEO Manish Gupta told Business Today.

MME will be the tenth health tech company to be acquired by Indegene, which was founded in 1998 by five first-generation entrepreneurs — Gupta, Dr. Rajesh Nair, Dr. Sanjay Parikh, Gaurav Kapoor, and Anand Kiran. Later, Infosys founding member N S Raghavan also bought a stake as a secondary investor.

In February, the Carlyle Group and Brighton Park Capital invested over $200 million in the company. The founder promoters have about a one-third stake in the fast-growing and debt-free health specialist company, said Gupta.

He said Indegene had a topline growth of over 25 percent and EBITDA compounded annual growth rate (CAGR) of 33 percent in the last decade. Topline growth in 2020-21 was about 45 percent and is expected to grow over 50 percent this year to post about $200 million in revenue. The company spent about $30-40 million in acquisitions and the majority of these funds were mobilized from internal accruals, said Gupta.

He said COVID-19 has accelerated digitization in the life sciences industries. Emerging biotech organizations today contribute about 75 percent of new drugs in the pipeline and this is only expected to grow, giving opportunities for specialists like Indegene.

Indegene is among the global leaders in providing digital transformation to life sciences companies. It employs more than 4,500 people across North America, Europe, China, Japan, and India, providing technology platforms and commercialization services to pharmaceutical, biotechnology, and medical device companies.

It helps companies design, build, and manage digital-first operations that leverage data and automation to accelerate clinical development, improve regulatory compliance, enhance customer experience, and drive commercial success.

News Source: BuisnessToday.In